Annals of Long Term Care

On March 5, a symposium entitled “Cholinesterase Inhibitors Across Stages of Dementia and Cognitive Impairments in the Elderly” was held at the 2005 Annual Meeting of the American Association for Geriatric Psychiatry. Presenters discussed the recognition and treatment of mild cognitive impairment; Alzheimer’s disease and its response to cholinesterase inhibitors; the management of cognitive and behavioral symptoms of dementia with Lewy bodies; and the response of Parkinson’s disease dementia to cholinesterase inhibitors.

CME Certified

CME Accreditation

This activity was developed for primary care physicians and geriatric psychiatrists.

Educational Objectives
Upon completion of this activity, participants should be able to:
• Discuss diagnostic criteria and treatment options for dementia with Lewy bodies, Parkinson’s disease with dementia, and Alzheimer’s disease.
• Identify specific symptoms that may indicate the onset of mild cognitive impairment.
• Review strategies for maximizing the use of cholinesterase inhibitors, and to identify potential future applications of cholinergic therapy for various dementias and mild cognitive impairment.

Sponsorship
This activity is sponsored by the American Association for Geriatric Psychiatry.

Accreditation
The American Association for Geriatric Psychiatry (AAGP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AAGP designates this continuing educational activity for a maximum of one Category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This CME activity was planned and produced in accordance with the ACCME Essentials.
Based upon trials, the estimated time to complete this activity is 1 hour.

Educational Grant
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Faculty Disclosure Information
The American Association for Geriatric Psychiatry requires that the authors participating in a continuing medical education activity disclose to participants any significant financial interest or other relationship (1) with the manufacturers of any commercial service discussed in an educational presentation, and (2) with any commercial supporters of the activity.

Soo Borson, MD, reported that she has received grant/research support from, has served as a consultant to, and/or is on the speakers’ bureau of Forest Pharmaceuticals, Inc., Janssen Pharmaceutica Products, LP, Novartis Pharmaceuticals Corporation, and Pfizer Inc.

Her presentation will discuss the unapproved use of cholinesterase inhibitors for mild cognitive impairment.

Martin R. Farlow, MD, reported that he has received grants from, is a consultant to, and/or is on the speakers’ bureau of Acellera, Best Practice, Eisai/Pfizer Inc, Elan Pharmaceuticals, Inc., Eli Lilly and Company, Eunoe Inc, Forest Laboratories, Inc. and Research Institute, GlaxoSmithKline, Memory Pharmaceuticals Corp., Novartis Pharmaceuticals Corporation, Ono Pharmaceuticals, PharmaNet, LLC, and Sanofi-Synthelabo Inc.

His presentation will not discuss the unapproved use of any drug or device.

George T. Grossberg, MD, reported that he has received grant/research support from and/or has served as a consultant to Abbott Laboratories, AstraZeneca Pharmaceuticals, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Pharmaceuticals, Inc., Janssen Pharmaceutica Products, LP, KV Pharmaceutical Co., Novartis Pharmaceuticals Corporation, Ono Pharmaceuticals, Organon, Inc., Pfizer Inc, Sanofi-Aventis, Sanofi-Synthelabo Inc., and Wyeth Pharmaceuticals.

His presentation will discuss the unapproved use of cholinesterase inhibitors for mild cognitive impairment.

Daniel I.